Pham, Minh C. http://orcid.org/0000-0003-0234-4790
Masi, Gianvito http://orcid.org/0000-0003-4754-2141
Patzina, Rosa http://orcid.org/0000-0002-1425-818X
Obaid, Abeer H. http://orcid.org/0000-0002-9846-1045
Oxendine, Seneca R. http://orcid.org/0000-0001-7354-973X
Oh, Sangwook http://orcid.org/0000-0003-0092-9031
Payne, Aimee S. http://orcid.org/0000-0001-9389-7918
Nowak, Richard J. http://orcid.org/0000-0001-8438-482X
O’Connor, Kevin C. http://orcid.org/0000-0002-7056-419X
Funding for this research was provided by:
Foundation for the National Institutes of Health (T32AI007019-46, AI114780, AI142198, U54-NS115054)
Rare Diseases Clinical Research Network (NS115054)
Article History
Received: 5 January 2023
Revised: 15 June 2023
Accepted: 16 June 2023
First Online: 21 June 2023
Declarations
:
: Dr. Aimee S. Payne has received equity, research support, patent licensing and other payments from Cabaletta Bio; patent licensing payments from Novartis; and consultant fees from Janssen. Dr. Sangwook Oh has received patent licensing payments from Cabaletta Bio. Dr. Richard J. Nowak has received research support from the NIH, Genentech, Alexion Pharmaceuticals, argenx, Annexon Biosciences, UCB Ra Pharmaceuticals, Myasthenia Gravis Foundation of America, Momenta, Immunovant, Grifols, and Viela Bio, now (Horizon Therapeutics). RJN has served as consultant/ advisor for Alexion Pharmaceuticals, argenx, Cabaletta Bio, CSL Behring, Grifols, Ra Pharmaceuticals, now a part of UCB Pharma, Immunovant, Momenta, and Viela Bio, now a part of Horizon Therapeutics; Dr. Kevin C. O’Connor has received research support from Ra Pharma, now (UCB Pharma), Alexion, now (AstraZeneca), Viela Bio, now (Horizon Therapeutics), and argenx. KCO is a consultant and equity shareholder of Cabaletta Bio. KCO has served as a consultant/advisor for Alexion Pharmaceuticals, now (AstraZeneca), and Roche. The authors have no additional financial interests. All other authors declare no competing financial interests.
: Deidentified human-derived specimens were retrieved from a biorepository established at the Yale University School of Medicine under the approval of Yale University’s Institutional Review Board.